BeiGene Is Keeping The Faith In IO/IO Combinations
Part 2 of 2
Executive Summary
Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments.
You may also be interested in...
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.
BeiGene’s Brukinsa Set To Take On Imbruvica With CLL Approval
The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.
Growing Pains: Charting The Rapid Rise Of Chinese IO
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.